Novo Nordisk's new weight loss oral medication is applying for clinical efficacy or surpassing smeglutide in China
Ty奇葩罗牛山831
发表于 2024-4-11 19:03:29
1219
0
0
On April 10th, the official website of the Drug Evaluation Center (CDE) of the National Medical Products Administration of China announced that the clinical trial application for the Class 1 new oral weight loss drug Amycretin tablets submitted by Novo Nordisk has been officially accepted.
Amycretin is another heavyweight loss therapy developed by Novo Nordisk, following Smegglutide. It is a novel oral GLP-1 receptor and Amylin receptor long-acting co agonist. A small Phase 1 clinical study recently released by Novo Nordisk showed that after 12 weeks of treatment with the drug, patients experienced an average weight loss of 13.1%, surpassing the weight loss efficacy of the old version of the semaglutide medication taken in the same cycle by 6%.
Novo Nordisk stated at last month's annual investor meeting that the mid-term trial of the drug will begin in the second half of this year and is expected to yield results in early 2026.
After the huge success of GLP-1 drugs, several companies are currently developing other promising new weight loss therapies, such as Amycretin, which targets amylin in the pancreas, which affects hunger. Similar to GLP-1, amylin can also slow down gastric emptying and promote satiety.
In addition to Novo Nordisk, another pharmaceutical company, Zealand, also has two pancreatic amyloid therapies under development. The company is also collaborating with German pharmaceutical company Boehringer Ingelheim to develop weight loss drugs.
Van Lanschot Kempen, a Dutch securities firm, believes that amyloid analogues are a "differentiated asset" in the weight-loss drug industry and can provide therapies tailored to different mechanisms.
On the other hand, oral versions of weight loss drugs have more advantages from the perspective of improving patient compliance. Novo Nordisk already has advantages in the development of oral therapies. In January this year, Novo Nordisk Megglutide Tablets was approved by the National Drug Administration (NMPA) for marketing. It is the first oral GLP-1 (glucagon like peptide-1) receptor agonist approved for marketing in China, which is used to treat adult type 2 diabetes.
At present, the oral preparation of Smegglutide for weight loss indications has entered phase 3 clinical trials in China, evaluating the efficacy and safety of 50mg oral preparation once daily in overweight or obese adults in China.
It is worth noting that the patent for Smegglutide compound in China will expire in 2026. On April 3rd, the official website of the Drug Evaluation Center of the National Medical Products Administration showed that Hangzhou Jiuyuan Genetic Engineering Co., Ltd.'s application for the listing of "Jiyoutai" injection of Smegglutide was accepted, making it the first Smegglutide biosimilar drug in mainland China to apply for listing.
In this context, Novo Nordisk's clinical application for the new generation GLP-1 class of drugs in China will help the company maintain its market advantage even after the expiration of the patent for Smegglutide.
Novo Nordisk also expects that the Wegovy injection, which is used for weight loss indications, is expected to be approved for sale in mainland China this year.
With Smegglutide, the market value of Novo Nordisk has exceeded $560 billion, surpassing Tesla's market value. The reason why GLP-1 drugs have ignited the capital market is because of their broader application prospects.
According to the latest research results published in the New England Journal of Medicine (NEJM) last Saturday, such hypoglycemic drugs can also reduce the risk of heart failure of diabetes patients with obesity related ejection fraction retention.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Novo Nordisk responds that semaglutide may cause male impotence
- How effective is the drug supply process initiated by Novo Nordisk for the approved slimming version of Smegglutide in China?
- Will Smegglutide's indications for treating obesity participate in this year's national medical insurance negotiations? Novo Nordisk responded by stating that they will immediately initiate internet access and hospital admissions in various regions
- Will the reduced weight version of Smegglutide be limited in supply to the Chinese market? Novo Nordisk responds
- The Battle of Weight Loss Drugs Begins: Smegglutide's Obesity Indications Approved in China
- "Weight loss pills" are sold in limited quantities in China? Novo Nordisk's latest response
- Yizi International expands its business in China and adds equity investment in Enxi Village
- Yizi International further expands its business in China and significantly increases its equity investment in Enxi Village
- Yizi International further expands its business in China and significantly increases its equity investment in Enxi Village
-
苹果知名分析师郭明錤周四(10月31日)在社交媒体上发文表示,苹果明年可能会减少对芯片制造商博通Wi-Fi芯片的依赖,并推出自己的处理器。 郭明錤在社交媒体平台X上写道,“在2025年下半年的新产品(例如iPh ...
- uturn
- 昨天 14:42
- 支持
- 反对
- 回复
- 收藏
-
10月30日,小鹏汽车生态企业小鹏汇天宣布,旗下分体式飞行汽车“陆地航母”即将亮相2024中国航展,11月12日将在中国航展第二展区(斗门莲洲)进行全球首次公开飞行,同时“陆地航母”也将在珠海国际航展中心8号 ...
- yxtianyouyou
- 前天 11:43
- 支持
- 反对
- 回复
- 收藏
-
交易所监管文件显示,当地时间11月1日,亚马逊创始人杰夫·贝索斯拟出售约1635万股亚马逊股票,预计套现约30.5亿美元。今年7月,贝索斯已申请额外出售约2500万股亚马逊股票,按当时股价计算可套现约50亿美元。 ...
- blueskybb
- 12 小时前
- 支持
- 反对
- 回复
- 收藏
-
近日,凯撒海湾目的地(山东)运营管理有限责任公司(简称“凯撒海湾”)与携程旅悦集团签署战略合作协议,双方将围绕“海上目的地运营”、“旅游产品与服务创新”、“研学旅行”、“日韩及海外旅游市场开拓”等 ...
- llyyy2008
- 11 小时前
- 支持
- 反对
- 回复
- 收藏